# AstraZeneca Plc aims for $80 billion in revenue by 2030

- Link: https://www.directorstalkinterviews.com/astrazeneca-plc-aims-for-80-billion-in-revenue-by-2030/4121157986
- Published: 2024-05-21T07:06:36+01:00
- Author: Amilia Stone

[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
has revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, 
up from $45.8 billion in 2023. This will be achieved through significant growth 
in its existing oncology, biopharmaceuticals and rare disease portfolio, and by 
launching an expected 20 new medicines before the end of the decade. To drive sustained
growth beyond 2030, the Company will continue investing in transformative new technologies
and platforms that will shape the future of medicine.

AstraZeneca will maintain its strategic commitment to R&D while focusing on productivity
throughout the Company, driving operating leverage and enabling the delivery of 
its ambition for a mid-30s percentage Core operating margin by 2026. Beyond 2026,
Core operating margin will be influenced by portfolio evolution and the company 
will target at least the mid-30s percentage range.

> **Pascal Soriot, Chief Executive Officer, said**: “Today AstraZeneca announces
> a new era of growth. In 2023 we delivered the ambitious $45 billion revenue goal
> set a decade ago. With the exciting growth of our innovative pipeline, which has
> the potential to transform millions of lives, we are now aiming for $80 billion
> by 2030.
> We are planning to launch 20 new medicines by 2030, many with the potential to
> generate more than $5 billion in peak year revenues. The breadth of our portfolio
> together with continued investment in innovation supports sustained growth well
> past the end of the decade.”

As AstraZeneca continues to grow across all therapy areas, it will continue to decouple
its carbon emissions from its increase in revenue. The Company has already reduced
its greenhouse gas emissions (Scopes 1 and 2) by 68% from its 2015 baseline while
growing Total Revenue by 85% over the same period. By 2026 the Company will be carbon
zero for Scope 1 and 2 emissions and by 2030 halve its Scope 3 emissions, on the
way to science-based net zero by 2045 at the latest.

**Notes****:**

A webcast of the Investor Day event will begin today, 21 May 2024, at 10:00 UK time.
Details can be found at www.astrazeneca.com/investor-relations/astrazeneca-investor-
day.html

**Basis of AstraZeneca’s ambitions, forecasts and targets**

AstraZeneca’s ambitions, forecasts and targets in this announcement (the “Financial
Ambition Statements”) are derived from AstraZeneca’s most recent risk-adjusted mid-
and long-term plans, adjusted for developments in the business since those plans
were finalised. The Financial Ambition Statements are based on management’s risk-
adjusted projections for individual medicines and individual clinical trials. Estimates
for these probabilities are based on industry-wide data for relevant clinical trials
in the pharmaceutical industry at a similar stage of development adjusted for management’s
view on the risk profile of the specific asset. The peak year revenue (PYR) potential
for individual medicines referred to in this announcement are the maximum estimated
Total Revenue to be recognised by AstraZeneca in a single calendar year, during 
the lifecycle of the medicine, and are based on management’s latest non-risk-adjusted
forecast estimates. Estimates are based on customary forecasting methodologies used
in the pharmaceutical industry. Peak year revenue may occur in different years for
each NME depending on trial outcomes, approval label, competition, launch dates 
and exclusivity periods, amongst other variables. The peak year revenue figures 
are derived from net sales at nominal values and are not risk-adjusted or time-value
discounted.  The development of pharmaceutical products has inherent risks given
scientific experimentation and there are a range of possible outcomes in clinical
results, safety, efficacy and product labelling. Clinical results may not achieve
the desired product profile and competitive environment, pricing and reimbursement
may have material impact on commercial revenue forecasts. By their nature, forecasts
are based on a multiplicity of assumptions and actual performance in future years
may vary, significantly and materially, from these assumptions. The Financial Ambition
Statements in this announcement are based on Q1 2024 exchange rates; AstraZeneca
undertakes no obligation to update those statements based on future currency movements.

Share on:
